Sub-categories

Choose categories from the dropdowns below to see different breakdowns of the data. Some will not be available until a higher level is chosen.

Download headline data (.csv) Download source data (.csv)

Download source data for disaggregations (.csv)

Headline data

Proportion of the target population covered by all vaccines included in their national programme
Year Value GeoCode SERIES
2007 94.1 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2008 95.3 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2009 95.4 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2010 96.5 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2011 95.1 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2012 96.2 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2013 96.9 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2014 95.8 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2015 96.6 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2016 96.1 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2017 93.4 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2018 94.5 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2019 94.351083 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2020 88.157251 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2021 88.796593 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2022 91.320114 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2023 87.939983 Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)
2007 98.8 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2008 99.1 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2009 98.9 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2010 98.3 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2011 97.2 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2012 97.7 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2013 98.666102 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2014 95.6 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2015 99.1 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2016 97.0 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2017 94.7 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2018 96.244215 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2019 97.245414 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2020 93.789319 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2021 93.378399 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2022 96.389079 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2023 98.924069 Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)
2015 96.8 Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3)
2016 97.2 Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3)
2017 94.2 Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3)
2018 92.0 Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3)
2019 95.083643 Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3)
2020 88.782542 Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3)
2021 89.631204 Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3)
2022 92.843773 Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3)
2023 70.959175 Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3)

Geographical Area: Кыргызская Республика

This table provides information about the indicator

Indicator name

3.b.1: Proportion of the target population covered by all vaccines included in their national programme
Target name

3.b: Support the research and development of vaccines and medicines for the communicable and non‑communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all
Goal

3: Ensure healthy lives and promote well-being for all at all ages

This table provides metadata for the actual indicator available from Kyrgyzstan statistics closest to the corresponding global SDG indicator. Please note that even when the global SDG indicator is fully available from Kyrgyz statistics, this table should be consulted for information on national methodology and other Kyrgyz-specific metadata information.

Geographical coverage

Кыргызская Республика
Unit of measurement

Процент
Definitions

Coverage of DTP containing vaccine (3rd dose): Percentage of surviving infants who received the 3 doses of diphtheria and tetanus toxoid with pertussis containing vaccine in a given year Coverage of Measles containing vaccine (2nd dose): Percentage of children who received two dose of measles containing vaccine according to nationally recommended schedule through routine immunization services. Coverage of Pneumococcal conjugate vaccine (last dose in the schedule): Percentage of surviving infants who received the recommended doses of pneumococcal conjugate vaccine.
Concepts

Immunization in the Kyrgyz Republic follows the National Calendar of Preventive Vaccinations, covering for almost all WHO recommended vaccines: BCG and Hepatitis B vaccines (within 24 hours from birth), three doses of a five-component vaccine with antigens of DPT, hepatitis B and hemophilus influenza type b (HIB), three doses of polio vaccine, three doses of pneumococcal (conjugate) vaccine, one dose of MMR vaccine with measles, rubella and mumps antigens. All vaccines must be given during the first year of life, except for PCC doses administered at 12 and 18 months of age.
Rationale and interpretation

Immunization is a proven tool for control and elimination of life-threatening communicable diseases and is one of the most cost-effective investments in health sector, which can be applied to even remote and most vulnerable populations.
Method of computation

Methodology estimates time series for national immunization coverage of target population with WHO recommended vaccines and those included in National Vaccines Calendar. Data have been produced and published annually since 2001. The methodology uses data reported by national health systems. Also administrative sources make it possible to calculate the coverage for each vaccine separately.
Comments and limitations

Countries often relay on administrative coverage data, while WHO and UNICEF review and assess data from different sources including administrative systems and surveys. Differences between country produced and international estimates are mainly due to differences between coverage estimates from administrative system and survey results. In case the vaccine is not included in national immunization schedule the coverage from private sector will not be reflected.
Quality assurance

Not available for this indicator
Data availability and gaps

Coverage data for different vaccines are collected annually and reviewed by WHO and UNICEF inter agency expert group and estimates made for each country and each year. Data are published both on WHO and UNICEF web sites. http://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.html http://www.data.unicef.org/child-health/immunization
Disaggregation

National and subnational estimates.
Comparability with international data/standards

The Kyrgyz Republic uses vaccines compliant with national requirements and WHO recommendations, as well as with international GMP standards, and have undergone WHO pre-qualification procedures.
References and documentation

http://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.html, https://www.unicef.org/immunization/
Data sources

Ministry of Health of the Kyrgyz Republic
Data collection methods

MoH administrative reporting
Link to UN metadata United Nations Sustainable Development Goals Metadata opens in a new window

This table provides information about the supplier of the data

Organization

National Statistical Committee of KR (Social Statistics Division), SRS under GKR, MoH KR
Contact person(s)/focal point

Rakhmanova Zh.Zh.
Contact person's email

rakhmanovazz@mail.ru
Contact person's phone

(0312) 32 46 52
Organization website

www.stat.kg
Back to top